secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001628280-23-015996
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Q1 net loss $13.4M; cash $117.7M; adds ROCK2 program via Graviton
----------------------------------------------------------------------

- Net loss $13.4M ($0.19 loss per share) vs $16.1M ($0.23) in Q1 2022; operating expenses $15.0M.
- Cash, equivalents and marketable securities $117.7M as of March 31; expected runway into 2025.
- Collaboration with Graviton adds GV101 (ROCK2 inhibitor); Phase 2 for brainstem cavernous malformations targeted for 2024.
- OV329 Phase 1 on track with no safety signals; full data expected H1 2024; OV350 advancing preclinically.
- Concluding Columbia University genetic collaboration by year-end; out-licensing options explored.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/0001628280-23-015996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/ovid-20230505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer